Clinical Trial Update: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Open-label Phase 3 extension trial of oral RPC1063 in relapsing multiple sclerosis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• RPC1063 (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2024-01-30